lilly_entrance_web

EU recommendation for Lilly’s soft tissue cancer drug

pharmafile | September 19, 2016 | News story | Sales and Marketing CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma 

The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with the rare cancer, soft tissue sarcoma.

Olaratumab is a human IgG1 monoclonal antibody that is designed to disrupt the PDGF Receptor-α (platelet-derived growth factor receptor α) pathway on tumour cells and on cells in the tumour microenvironment.

The pharma firm’s drug is to be used in combination with doxorubicin for treatment of the illness for whom surgery or radiotherapy is not suitable, and who have not been previously treated with doxorubicin.  

The FDA also fast-tracked review of the treatment in May.

The recommendation is based on data from Phase II of the JGDG study which showed a median improvement of 11.8 months in survival time of patients treated with a combination of doxorubicin plus Lartruvo compared to doxorubicin alone. The decision is thought to strongly encourage a marketing authorisation in the coming weeks.

Matt Fellows

Related Content

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …

Latest content